Renergen Limited and ASP Isotopes Inc. have announced an extension of the deadline for the fulfillment of outstanding conditions related to their Scheme of Arrangement. The companies have agreed to extend the deadline to January 30, 2026, to allow for additional time to obtain the required approvals.
Key milestone transaction approvals have already been received, including the approval from the Competition Commission, paving the way for the two companies to plan integration processes and begin collaborating. The written consent to the transfer of Renergen Shares has been obtained from the Industrial Development Corporation of South Africa and the United States International Development Finance Corporation, fulfilling the relevant Offer Condition.
As for the ASPI Funding Arrangements, the date for Renergen’s repayment of the funding advanced to it has been extended to January 30, 2026, by agreement between the parties.
Both Renergen and ASPI remain fully committed to the Scheme and are making progress in fulfilling the final outstanding Conditions, while working together to obtain the required approvals as quickly as possible.
The companies have assured shareholders that once the remaining Conditions have been fulfilled (or if applicable waived), they will announce the updated salient dates and times for the Scheme on SENS and on the ASX. Following these announcements, the company's shares moved 5.07%, and are now trading at a price of $6.22. Check out the company's full 8-K submission here.
